产品名称

GW 9662

产品货号

Axon 2262 CAS [22978-25-2] MF C13H9ClN2O3MW 276.68 Purity: 100% Soluble in DMSO and Ethanol Description Potent PPARγ antagonist (IC50 values 3.3 nM, 32 nM and 2000 nM for PPARγ, PPARα, and PPARδ, respectively) which inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. GW 9662 profoundly improved healing and induced angiogenesis in human mesenchymal stem cells (hMSCs), and reversed the protection of endotoxin (lipopolysaccharide, LPS) in a model of renal ischemia-reperfusion. References Certificates Categories Extra info U. Krause et al. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. PNAS USA 2010, 107, 4147-4152. J.M. Seargent et al. GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. Br. J. Pharmacol. 2004, 143, 933-937. M. Collino et al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005, 68, 529-536. L.M. Leesnitzer et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochem. 2002, 41, 6640-6650. Certificate of Analysis Material Safety Data Sheet Diabetes & Metabolism PPAR NR1C Selective PPARγ antagonist Chemical name 2-chloro-5-nitro-N-phenylbenzamide Parent CAS No. [22978-25-2] Order Size Unit Price Stock 10 mg €60.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

GW 9662

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 2262

CAS [22978-25-2]

MF C13H9ClN2O3
MW 276.68

Purity: 100%
Soluble in DMSO and Ethanol

GW 9662

Description

Potent PPARγ antagonist (IC50 values 3.3 nM, 32 nM and 2000 nM for PPARγ, PPARα, and PPARδ, respectively) which inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. GW 9662 profoundly improved healing and induced angiogenesis in human mesenchymal stem cells (hMSCs), and reversed the protection of endotoxin (lipopolysaccharide, LPS) in a model of renal ischemia-reperfusion.

U. Krause et al. Pharmaceutical modulation of canonical Wnt signaling in multipotent stromal cells for improved osteoinductive therapy. PNAS USA 2010, 107, 4147-4152.

J.M. Seargent et al. GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation. Br. J. Pharmacol. 2004, 143, 933-937.

M. Collino et al. The selective PPARgamma antagonist GW9662 reverses the protection of LPS in a model of renal ischemia-reperfusion. Kidney Int. 2005, 68, 529-536.

L.M. Leesnitzer et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochem. 2002, 41, 6640-6650.

Selective PPARγ antagonist

Chemical name

2-chloro-5-nitro-N-phenylbenzamide

Parent CAS No.

[22978-25-2]

产品资料